Zeposia 0.23 mg hard capsules Zeposia 0.46 mg hard capsules clinical trials

A Phase 2/3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Participants with Moderately to Severely Active Crohn’s Disease with an Inadequate Response to Conventional Therapy

This study is looking at a new medicine called Zeposia for children and young people with Crohn's disease that hasn't responded well to other treatments. Researchers want to see if Zeposia can help improve symptoms and how safe it is over time.